注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Aquestive Therapeutics Inc是一家制药公司。该公司从事开发口服给药产品以传递分子,提供护理疗法的替代品。该公司致力于推进以治疗中枢神经系统(CNS)疾病为重点的后期产品线,以及用于治疗包括过敏反应在内的严重过敏反应的早期产品线。该公司专注于癫痫的CNS产品组合包括Sympazan和Libervant。其复杂分子管道产品组合中的活跃项目有:AQST-109-SF、AQST-108-SF和AQST-108-SF。其PharmFilm技术开发的药物可提供无创给药、为吞咽困难患者量身定制的适用性,无需水即可给药,并确保一致的治疗剂量。PharmFilm由用作成膜剂的聚合物组合物组成,可将活性药物成分(API)和赋形剂固定在适当的位置。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Gregory Bailey Brown | 71 | 2007 | Independent Director |
John Shannon Cochran | 58 | 2004 | Independent Vice Chairman of the Board |
Daniel Barber | 48 | 2014 | CEO, President & Director |
Jay Lieberman | - | 2022 | Member of Scientific Advisory Board |
Santo J. Costa | 78 | 2015 | Independent Chairman of the Board |
Timothy E. Morris | 63 | 2022 | Independent Director |
Julie Krop | 58 | 2021 | Independent Director |
David B. Golden | - | 2022 | Member of Scientific Advisory Board |
David M. Fleischer | - | 2022 | Member of Scientific Advisory Board |
John Oppenheimer | - | 2022 | Member of Scientific Advisory Board |
David I. Bernstein | - | 2022 | Member of Scientific Advisory Board |
Marco Taglietti | 64 | 2021 | Independent Director |
Ruchi S. Gupta | - | 2022 | Member of Scientific Advisory Board |
Matthew Greenhawt | - | 2022 | Member of Scientific Advisory Board |
Carlos Camargo | - | 2022 | Member of Scientific Advisory Board |
Abigail L. Jenkins | 48 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核